Bifogade filer
Infant Bacterial Therapeutics (IBT) to Present Results of “The Connection Study” at PAS 2025 in Honolulu
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, “The Connection Study,” will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on Saturday, April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida.
The PAS 2025 Meeting, held from April 24–28, is a premier international forum for pediatric researchers, clinicians, and educators. IBT’s presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.
Presentation Details
Oral Presentation
- Title: Effects of IBP-9414, a Live Biotherapeutic Product, on NEC, Time to Full Enteral Feeding, and Mortality in Very Low Birth Weight Infants: Results from The Connection Study
- Presenter: Prof. Josef Neu, Principal Investigator, University of Florida
- Date & Time: Saturday, April 26, 2025 – 7:00 AM to 8:30 AM HST
- Location: Convention Center: Kalākaua Ballroom A (Level 4)
Poster Presentation
- Title: Effects of IBP-9414 vs Placebo on Time to Reach Sustained Full Enteral Feeding in Very Low Birth Weight (VLBW) Infants: Results from The Connection Study
- Presenter: Prof. Josef Neu, Principal Investigator, University of Florida
- Date & Time: Saturday, April 26, 2025 – 2:30 PM to 4:45 PM HST
- Location: Exhibit Hall, Hawaii Convention Center
About “The Connection Study”
The Connection Study is the largest randomized, double-blind, parallel-group, placebo-controlled trial to date evaluating the efficacy and safety of IBP-9414 in premature infants (birth weight 500–1500g) for the prevention of necrotizing enterocolitis (NEC) — a life-threatening condition in neonates.
For more information about IBT and The Connection Study, please visit www.ibtherapeutics.com. Details about the PAS 2025 Meeting can be found at www.pas-meeting.org.